Dyadic International, Inc. · NASDAQ:DYAI
Dyadic International — H.C. Wainwright Global Investment Conference May 2022
17 slides from Dyadic International's conference presentation, May 2022
Slide 1: Next Generation Proteins for the World's Health
Dyadic International (NASDAQ: DYAI) Next Generation Proteins for the World’s Health H.C. Wainwright Global Investment Conference May 2022
Slide 2: Safe Harbor Regarding Forward-looking Statements
Safe Harbor Regarding Forward-looking Statements Certain statements contained in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic’s expectations, i
Slide 3: Dyadic's Mission
Dyadic’s Mission To improve how we feed, fuel, and heal the world by utilizing modern biotechnology to revolutionize science, medicine, agriculture. We are delivering a proven, cost-effective, industrial protein expression platform, which can fulfill the promise of affordable biologic drugs, vaccine
Slide 4: Dyadic At-a-Glance
Dyadic At-a-Glance Re-engineering GMP Vaccine & Drug Production: Proprietary & patented protein expression platform focused on biologic and vaccine production (the “C1 Platform”), designed to bring products requiring protein expression to market faster, in greater volumes, at lower cost. The C1 plat
Slide 5: Proven Leaders to Execute Dyadic Keys to Success
Proven Leaders to Execute Dyadic Keys to Success Joe Hazelton, CBO Mark Emalfarb, Founder/CEO 20+ Years in Pharmaceutical Industry, commercialization, Entrepreneur, Inventor 25+ U.S. and foreign biotechnology regulatory, business and clinical development patents, filamentous fugal enzyme product com
Slide 6: C1 Uniquely Positioned to Address Vaccine and Biologic Challenges
C1 Uniquely Positioned to Address Vaccine and Biologic Challenges Manufacturing Challenges C1 Manufacturing Advantages 20+ years of proven industrial large-scale manufacturing Shortened timeframes and shortage of raw materials, equipment, Material and consumables, lipid nanoparticles due to high dem
Slide 7: Key Advantages: C1 Protein Production Capability
Key Advantages: C1 Protein Production Capability Potential to disrupt conventional manufacturing platforms by overcoming key production limitations • High retention of target secreted protein through downstream processing Purity • No requirement for viral (i.e., CHO) or endotoxin ( i.e., E.coli) ina
Slide 8: C1 is the Foundation for Our Core Business Segments
C1 is the Foundation for Our Core Business Segments C1-cell Protein Production Platform Human Health Animal Health Other Biomolecules Phase 1 Clinical Trial of DYAI-100, COVID-19 Advance commercial recombinant antigen Strategic partnership with a Global Food Ingredient (RBD) recombinant protein vacc
Slide 9: C1-cell Protein Production Platform Has Been Validated by ZAPI
C1-cell Protein Production Platform Has Been Validated by ZAPI $20MM PROGRAM OVER 5 YEAR S EU sponsored Zoonosis Anticipation Preparedness Initiative (ZAPI) Zoonoses, like Ebola and influenza, represent a serious threat to both human and animal health Experts in human and animal health New platforms
Slide 10: Key Milestone
Key Milestone Phase I C1-cell SARS-CoV-2 RBD Recombinant Vaccine. Prove Safety and Efficacy of DYAI-100 Vaccine Candidate in Humans = Completed = Ongoing Developed the C1 –SARS-CoV-2 RBD protein based rVaccine (DYAI-100 Vaccine Candidate) Development of Monovalent RBD characterization / evaluation C
Slide 11: Key Partners: Establishing Global Presence with Leading Organizations
Key Partners: Establishing Global Presence with Leading Organizations Co-developing C1 enabled vaccines, antibodies & other therapeutics for human and animal health Research, License and Collaboration Dyadic announces development of COVID-19 Agreement with Janssen Vaccine in India Under the terms of
Slide 12: 2022 Year-to-Date Agreements / Events
2022 Year-to-Date Agreements / Events Development of C1-cell Protein Production Platform for Commercial Use Matures Date Agreement / Events 5/22 Research, license and collaboration for the manufacture of animal free ingredients, fully funded (€3.6M) by a global food ingredients company 5/22 3rd peer
Slide 13: Key Focus: Infectious Disease Strategy For Animal and Human Health
Key Focus: Infectious Disease Strategy For Animal and Human Health Potential to Develop Multi-Valent Recombinant Variant Antigens (i.e., SARS-CoV-2 and Influenza) Vaccine Candidates All variants of concern SARS-CoV-2 Univ. Oslo HA mice trial supports previous C1 Monoclonal antibodies (mAbs) Receptor
Slide 14: Key Attributes: C1-Cell Recombinant Protein Production for Biologics
Key Attributes: C1-Cell Recombinant Protein Production for Biologics C1-Cells Enable Commercial Manufacture Of Rapid, Cost-Effective, High Value, Safe, Effective Protein Products High Yields and Purities Demonstrated for Therapeutic Monoclonal Antibodies (mAbs) and Vaccine Antigen GlycoProteins1 Fab
Slide 15: Rising Interest in Pharma for Acquisition of Platform Technologies
Rising Interest in Pharma for Acquisition of Platform Technologies1 Recent acquisitions of cell-based gene expression and recombinant protein platforms 2011 2006 Johnson & Johnson Acquires Vaccine Merck & Co., Inc. To Acquire GlycoFi, Developer Crucell - $2.4 billion dollars, Inc. For $400 Million 2
Slide 16: Key Takeaways
Key Takeaways Next Generation Protein Production Biotech with Well-established Global Partners Lead asset: DYAI-100, Multiple shots on goal Strong cash position COVID-19 Vaccine Candidate “Pre-IND” first-in-human clinical trial High demand for R&D collaborations $17.5 million in cash and investment
Slide 17: Thank You
THANK YOU Contact: ir@dyadic.com I www.dyadic.com
Dyadic International — H.C. Wainwright Global Investment Conference May 2022 on 6ix